BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge
Cancers · 04.05.2023 · 15 (9) · 2607
DOI: 10.3390/cancers15092607 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 04.05.2023. Verfasst von Laetitia Florent und 3 weiteren Autor:innen. Beteiligte Einrichtung: Université de Reims Champagne-Ardenne, UFR de Pharmacie, BioSpecT EA 7506, 51097 Reims, France. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Melanoma is the most common cause of death in skin cancer due to its high metastatic potential. While targeted therapies have improved the care of patients with metastatic melanoma harboring the BRAFV600E mutation, these treatments are associated with a high frequency of resistance. Resistance factors are related to cellular adaptation as well as to changes in the tumor microenvironment. At the cellular level, resistance involves mutations, overexpression, activation, or inhibition of effectors involved in cell signaling pathways such as MAPK, PI3K/AKT, MITF, and epigenetic factors (miRNAs). In addition, several components of the melanoma microenvironment, such as soluble factors, collagen, and stromal cells also play a crucial role in this resistance. In fact, extracellular matrix remodeling impacts the physical and chemical properties with changes in the stiffness and acidity, respectively of the microenvironment. The cellular and immune components of the stroma are also affected, including immune cells and CAF. The aim of this manuscript is to review the mechanisms responsible for resistance to targeted therapies in BRAFV600E-mutated metastatic melanoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Université de Reims Champagne-Ardenne, UFR de Pharmacie, BioSpecT EA 7506, 51097 Reims, France.
- CHU Reims, Department of Pharmacy, 51097 Reims, France.
ORCID-Profile: Florian Slimano
Zitieren
APA
Florent, L., Saby, C., Slimano, F., & Morjani, H. (2023). BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge. Cancers, 15(9), 2607. https://doi.org/10.3390/cancers15092607
Vancouver
Florent L, Saby C, Slimano F, Morjani H. BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge. Cancers. 2023;15(9):2607. doi:10.3390/cancers15092607
BibTeX
@article{Florent2023,
author = {Florent, Laetitia and Saby, Charles and Slimano, Florian and Morjani, Hamid},
title = {BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge},
journal = {Cancers},
year = {2023},
volume = {15},
number = {9},
pages = {2607},
doi = {10.3390/cancers15092607}
}
EUVIMED